• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

chronic lymphocytic leukaemia (CLL) - Articles and news items

ofatumumab-genmab

FDA approves Genmab’s ofatumumab for relapsed CLL

Industry news / 31 August 2016 / Niamh Louise Marriott, Digital Content Producer

Approval is supported by the Phase III complement study that evaluated ofatumumab in combination with FC versus FC alone in patients with relapsed CLL…

 

Win an Amazon Gift Card worth up to €100!TAKE OUR SURVEY
+ +